Combination of immunotherapy with cyclophosphamide/ actinomycin D chemotherapy potentiates antileukemic effect and reduces toxicity in a L1210 leukemia model in mice
- 10 February 1995
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 89 (1) , 137-143
- https://doi.org/10.1016/0304-3835(95)90169-8
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalanCancer, 1994
- Leukemic Cell Lysis by Activated Human Macrophages: Significance of Membrane-associated Tumor Necrosis FactorJapanese Journal of Cancer Research, 1993
- Phase I Trial of Interleukin-2 plus DoxorubicinJournal of Immunotherapy, 1993
- Interleukin-2 in cancer treatment: Disappointing or (still) promising? A reviewCancer Immunology, Immunotherapy, 1993
- Antitumor Effect of Thymosin α1/Interleukin-2 or Thymosin α1/Interferon α,β Following Cyclophosphamide in Mice Injected with Highly Metastatic Friend Erythroleukemia CellsJournal of Immunotherapy, 1993
- Combination tumor-immunotherapy with recombinant tumor necrosis factor and recombinant interleukin 2 in miceInternational Journal of Cancer, 1987
- Anti‐tumor effects of tumor necrosis factor in combination with chemotherapeutic agentsInternational Journal of Cancer, 1987
- Recombinant human TNF induces production of granulocyte–monocyte colony-stimulating factorNature, 1986
- Recombinant Human Tumor Necrosis Factor-α: Effects on Proliferation of Normal and Transformed Cells in VitroScience, 1985
- Effect of Cyclophosphamide on Immunological Control MechanismsImmunological Reviews, 1982